Leo Ruhnke
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.
Journal: Transplantation and cellular therapy
Published: August 26, 2026
Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.
Journal: Leukemia & lymphoma
Published: August 02, 2026
Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.
Journal: Haematologica
Published: April 20, 2026
Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.
Journal: Haematologica
Published: December 23, 2025
Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow.
Journal: Cytometry. Part B, Clinical cytometry
Published: September 18, 2025
Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.
Journal: HemaSphere
Published: September 05, 2025
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: September 01, 2025
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
Journal: Blood
Published: August 19, 2025
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.
Journal: Blood
Published: August 19, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Journal: American journal of hematology
Published: June 25, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
Journal: Annals of hematology
Published: April 20, 2025
Last Updated: 09/26/2026